{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:32:51Z","timestamp":1791484371006,"version":"4.3.4"},"reference-count":85,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":1054,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s13311-020-00914-6","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T16:04:39Z","timestamp":1598544279000},"page":"1681-1693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"title":["Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments"],"prefix":"10.1016","volume":"17","author":[{"given":"Andrew","family":"Billnitzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-020-00914-6_bib1","unstructured":"Association D-5 AP. Diagnostic and statistical manual of mental disorders 2013."},{"key":"10.1007\/s13311-020-00914-6_bib2","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1212\/CON.0000000000000752","article-title":"Tics and Tourette syndrome","volume":"25","author":"Singer","year":"2019","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1007\/s13311-020-00914-6_bib3","doi-asserted-by":"crossref","unstructured":"Jankovic J. Treatment of tics associated with Tourette syndrome. J Neural Transm 2020. https:\/\/doi.org\/10.1007\/s00702-019-02105-w.","DOI":"10.1007\/s00702-019-02105-w"},{"key":"10.1007\/s13311-020-00914-6_bib4","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1212\/WNL.0000000000007466","article-title":"Practice guideline recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders","volume":"92","author":"Pringsheim","year":"2019","journal-title":"Neurology"},{"key":"10.1007\/s13311-020-00914-6_bib5","doi-asserted-by":"crossref","unstructured":"Stafford M, Cavanna AE Prevalence and clinical correlates of self-injurious behavior in Tourette syndrome. Neurosci Biobehav Rev 2020","DOI":"10.1016\/j.neubiorev.2020.03.022"},{"key":"10.1007\/s13311-020-00914-6_bib6","doi-asserted-by":"crossref","unstructured":"Martino D, Pringsheim TM. Tourette syndrome and other chronic tic disorders: an update on clinical management. Expert Review of Neurotherapeutics 2017. https:\/\/doi.org\/10.1080\/14737175.2018.1413938.","DOI":"10.1080\/14737175.2018.1413938"},{"key":"10.1007\/s13311-020-00914-6_bib7","doi-asserted-by":"crossref","unstructured":"Nussey C, Pistrang N, Murphy T, Nussey C, Older B. How does psychoeducation help? A review of the effects of providing information about Tourette syndrome and attention-deficit\/hyperactivity disorder 2013. https:\/\/doi.org\/10.1111\/cch.12039.","DOI":"10.1111\/cch.12039"},{"key":"10.1007\/s13311-020-00914-6_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11920-019-1018-z","article-title":"Advances in the treatment of Tourette's disorder","volume":"21","author":"Chadehumbe","year":"2019","journal-title":"Curr Psychiatry Rep"},{"key":"10.1007\/s13311-020-00914-6_bib9","doi-asserted-by":"crossref","unstructured":"Jackson SR, Loayza J, Crighton M, Sigurdsson HP, Dyke K, Jackson GM. The role of the insula in the generation of motor tics and the experience of the premonitory urge-to-tic in Tourette syndrome. Cortex 2020. https:\/\/doi.org\/10.1016\/j.cortex.2019.12.021.","DOI":"10.1101\/2020.01.29.924399"},{"key":"10.1007\/s13311-020-00914-6_bib10","doi-asserted-by":"crossref","unstructured":"Patel N, Jankovic J, Hallett M. Sensory aspects of movement disorders. Lancet Neurol 2014. https:\/\/doi.org\/10.1016\/S1474-4422(13)70213-8.","DOI":"10.1016\/S1474-4422(13)70213-8"},{"key":"10.1007\/s13311-020-00914-6_bib11","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1001\/jama.2010.607","article-title":"Behavior therapy for children with Tourette disorder: a randomized controlled trial","volume":"303","author":"Piacentini","year":"2010","journal-title":"JAMA"},{"key":"10.1007\/s13311-020-00914-6_bib12","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1001\/archgenpsychiatry.2011.1528","article-title":"Randomized trial of behavior therapy for adults with Tourette syndrome","volume":"69","author":"Wilhelm","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"10.1007\/s13311-020-00914-6_bib13","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jpsychires.2013.12.009","article-title":"A meta-analysis of behavior therapy for Tourette Syndrome","volume":"50","author":"McGuire","year":"2014","journal-title":"J Psychiatr Res"},{"key":"10.1007\/s13311-020-00914-6_bib14","unstructured":"Internet-based CBIT for children with chronic tics. ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/ct2\/shorrw\/NCT04087616?term=cbit&cond=Tourette+Syndrome&draw=2&rank=3 (accessed March 10, 2020)."},{"key":"10.1007\/s13311-020-00914-6_bib15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/NRL.0000000000000218","article-title":"Progress in pharmacological and surgical management of Tourette syndrome and other chronic tic disorders","volume":"24","author":"Pandey","year":"2019","journal-title":"Neurologist"},{"key":"10.1007\/s13311-020-00914-6_bib16","doi-asserted-by":"crossref","unstructured":"Pringsheim T, Marras C. Pimozide for tics in Tourette's syndrome. Cochrane Database Syst Rev 2009. https:\/\/doi.org\/10.1002\/14651858.CD006996.pub2.","DOI":"10.1002\/14651858.CD006996.pub2"},{"key":"10.1007\/s13311-020-00914-6_bib17","doi-asserted-by":"crossref","unstructured":"Curtis A, Clarke CE, Rickards HE. Cannabinoids for Tourette's syndrome. Cochrane Database Syst Rev 2009. https:\/\/doi.org\/10.1002\/14651858.cd006565.pub2.","DOI":"10.1002\/14651858.CD006565.pub2"},{"key":"10.1007\/s13311-020-00914-6_bib18","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1176\/appi.ajp.158.7.1067","article-title":"A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder","volume":"158","author":"Scahill","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1007\/s13311-020-00914-6_bib19","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1097\/00004583-199509000-00010","article-title":"Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience","volume":"34","author":"Chappell","year":"1995","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1007\/s13311-020-00914-6_bib20","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00002826-200211000-00009","article-title":"Neuropsychiatric effects of guanfacine in children with mild Tourette syndrome: a pilot study","volume":"25","author":"Cummings","year":"2002","journal-title":"Clin Neuropharmacol"},{"key":"10.1007\/s13311-020-00914-6_bib21","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1212\/WNL.58.4.527","article-title":"Treatment of ADHD in children with tics: a randomized controlled trial","volume":"58","author":"Tourette's Syndrome Study Group","year":"2002","journal-title":"Neurology"},{"key":"10.1007\/s13311-020-00914-6_bib22","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1089\/cap.2017.0024","article-title":"Extended-release guanfacine does not show a large effect on tic severity in children with chronic tic disorders","volume":"27","author":"Murphy","year":"2017","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1007\/s13311-020-00914-6_bib23","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/00048670802277222","article-title":"Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders","volume":"42","author":"Du","year":"2008","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1007\/s13311-020-00914-6_bib24","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.neubiorev.2012.09.008","article-title":"Systematic review: pharmacological treatment of tic disorders\u2013efficacy of antipsychotic and alpha-2 adrenergic agonist agents","volume":"37","author":"Weisman","year":"2013","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1007\/s13311-020-00914-6_bib25","doi-asserted-by":"crossref","unstructured":"Osland ST, Steeves TDL, Pringsheim T. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev 2018;2018. https:\/\/doi.org\/10.1002\/14651858.CD007990.pub3.","DOI":"10.1002\/14651858.CD007990.pub3"},{"key":"10.1007\/s13311-020-00914-6_bib26","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/WNF.0b013e3181c295c1","article-title":"Topiramate in treatment of tourette syndrome","volume":"33","author":"Kuo","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"10.1007\/s13311-020-00914-6_bib27","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/jnnp.2009.185348","article-title":"A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome","volume":"81","author":"Jankovic","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-020-00914-6_bib28","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.pediatrneurol.2013.05.002","article-title":"Topiramate for Tourette's syndrome in children: a meta-analysis","volume":"49","author":"Yang","year":"2013","journal-title":"Pediatr Neurol"},{"key":"10.1007\/s13311-020-00914-6_bib29","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00004583-200003000-00010","article-title":"Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study","volume":"39","author":"Sallee","year":"2000","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1007\/s13311-020-00914-6_bib30","doi-asserted-by":"crossref","unstructured":"Yoo HK, Joung YS, Lee JS, Song DH, Lee YS, Kim JW, et al. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette's disorder. J Clin Psychiatry 2013;74. https:\/\/doi.org\/10.4088\/JCP.12m08189.","DOI":"10.4088\/JCP.12m08189"},{"key":"10.1007\/s13311-020-00914-6_bib31","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1089\/cap.2016.0026","article-title":"Randomized, double-blind, placebo-controlled trial demonstrates the efficacy and safety of oral aripiprazole for the treatment of Tourette's disorder in children and adolescents","volume":"27","author":"Sallee","year":"2017","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1007\/s13311-020-00914-6_bib32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00004714-200202000-00006","article-title":"Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial","volume":"22","author":"Dion","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"10.1007\/s13311-020-00914-6_bib33","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1212\/01.WNL.0000055434.39968.67","article-title":"A placebo-controlled trial of risperidone in Tourette syndrome","volume":"60","author":"Scahill","year":"2003","journal-title":"Neurology"},{"key":"10.1007\/s13311-020-00914-6_bib34","doi-asserted-by":"crossref","unstructured":"Pe\u00f1a MS, Yaltho TC, Jankovic J. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord 2011. https:\/\/doi.org\/10.1002\/mds.23402.","DOI":"10.1002\/mds.23402"},{"key":"10.1007\/s13311-020-00914-6_bib35","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1089\/cap.2007.135","article-title":"Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome","volume":"18","author":"McCracken","year":"2008","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1007\/s13311-020-00914-6_bib36","doi-asserted-by":"crossref","unstructured":"Wijemanne S, Wu LJC, Jankovic J. Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Mov Disord 2014. https:\/\/doi.org\/10.1002\/mds.25692.","DOI":"10.1002\/mds.25692"},{"key":"10.1007\/s13311-020-00914-6_bib37","doi-asserted-by":"crossref","unstructured":"Brander G, Isomura K, Chang Z, Kuja-Halkola R, Almqvist C, Larsson H, et al. Association of Tourette syndrome and chronic tic disorder with metabolic and cardiovascular disorders. JAMA Neurol 2019. https:\/\/doi.org\/10.1001\/jamaneurol.2018.4279.","DOI":"10.1001\/jamaneurol.2018.4279"},{"key":"10.1007\/s13311-020-00914-6_bib38","doi-asserted-by":"crossref","unstructured":"Savitt D, Jankovic J. Tardive syndromes. J Neurol Sci 2018. https:\/\/doi.org\/10.1016\/j.jns.2018.02.005.","DOI":"10.1016\/j.jns.2018.02.005"},{"key":"10.1007\/s13311-020-00914-6_bib39","doi-asserted-by":"crossref","unstructured":"Frei K, Truong DD, Fahn S, Jankovic J, Hauser RA. The nosology of tardive syndromes. J Neurol Sci 2018. https:\/\/doi.org\/10.1016\/j.jns.2018.02.008.","DOI":"10.1016\/j.jns.2018.02.008"},{"key":"10.1007\/s13311-020-00914-6_bib40","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1080\/14656566.2016.1258063","article-title":"Dopamine depleters in the treatment of hyperkinetic movement disorders","volume":"17","author":"Jankovic","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1007\/s13311-020-00914-6_bib41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/WNF.0000000000000326","article-title":"Real-world experience with VMAT2 inhibitors","volume":"42","author":"Niemann","year":"2019","journal-title":"Clin Neuropharmacol"},{"key":"10.1007\/s13311-020-00914-6_bib42","doi-asserted-by":"crossref","first-page":"422","DOI":"10.5334\/tohm.287","article-title":"Deutetrabenazine in tics associated with Tourette syndrome","volume":"6","author":"Jankovic","year":"2016","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"10.1007\/s13311-020-00914-6_bib43","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/00044011-200828070-00006","article-title":"Tourette's syndrome and role of tetrabenazine: review and personal experience","volume":"28","author":"Porta","year":"2008","journal-title":"Clin Drug Investig"},{"key":"10.1007\/s13311-020-00914-6_bib44","unstructured":"Coffey B, Jankovic J, Claassem D, Jimenez-Shahed J, Gertz B, Garofalo E, et al. Efficacy and safety of deutetrabenazine treatment for Tourette syndrome in children and adolescents: results from the ARTISTS 1 and ARTISTS 2 studies. Presented at the Tourette Association of America's Inaugural Virtual Conference. https:\/\/tourette.org\/about-tourette\/virtual-conference\/. Accessed 15 May 2020."},{"key":"10.1007\/s13311-020-00914-6_bib45","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1177\/0883073807307108","article-title":"Comparison of weight gain in treatments for tourette syndrome: tetrabenazine versus neuroleptic drugs","volume":"23","author":"Ondo","year":"2008","journal-title":"J Child Neurol"},{"key":"10.1007\/s13311-020-00914-6_bib46","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0022-3565(25)13263-1","article-title":"Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity","volume":"247","author":"Chipkin","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1007\/s13311-020-00914-6_bib47","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF02246068","article-title":"Lack of apparent antipsychotic effect of the D1-dopamine recepotr antagonist SCH39166 in acutely ill schizophrenic patients","volume":"121","author":"Karlsson","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1007\/s13311-020-00914-6_bib48","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/WNF.0000000000000017","article-title":"A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome","volume":"37","author":"Gilbert","year":"2014","journal-title":"Clin Neuropharmacol"},{"issue":"8","key":"10.1007\/s13311-020-00914-6_bib49","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/mds.27457","article-title":"Ecopipam, a D1 receptor antagonist, for treatment of Tourette syndrome in children: a randomized, placebo-controlled crossover study","volume":"33","author":"Gilbert","year":"2018","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-020-00914-6_bib50","unstructured":"Ecopipam tablets to study Tourette's syndrome in children and adolescents (D1AMOND). ClinicalTrialsGov 2019."},{"key":"10.1007\/s13311-020-00914-6_bib51","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1055\/s-2002-25028","article-title":"Treatment of Tourette's syndrome with \u03949-tetrahydrocannabinol (THC): a randomized crossover trial","volume":"35","author":"M\u00fcller-Vahl","year":"2002","journal-title":"Pharmacopsychiatry"},{"key":"10.1007\/s13311-020-00914-6_bib52","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4088\/JCP.v64n0417","article-title":"\u03949-Tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial","volume":"64","author":"M\u00fcller-Vahl","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1007\/s13311-020-00914-6_bib53","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.parkreldis.2018.10.004","article-title":"Single center experience with medical cannabis in Gilles de la Tourette syndrome","volume":"61","author":"Thaler","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1007\/s13311-020-00914-6_bib54","unstructured":"A study to examine the efficacy of a therapeutic THX-110 for Tourette syndrome. ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03651726?recrs=abdf&type=Intr&cond=Tourette+Syndrome&draw=2&rank=7 (accessed March 9, 2020)."},{"key":"10.1007\/s13311-020-00914-6_bib55","unstructured":"CANNAbinoids in the Treatment of TICS (CANNA-TICS). ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03087201?recrs=abdf&type=Intr&cond=Tourette+Syndrome&draw=2&rank=27 (accessed March 9, 2020)."},{"key":"10.1007\/s13311-020-00914-6_bib56","unstructured":"Safety and efficacy of cannabis in Tourette syndrome. ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03247244?recrs=abdf&type=Intr&cond=Tourette+Syndrome&draw=2&rank=4 (accessed March 9, 2020)."},{"key":"10.1007\/s13311-020-00914-6_bib57","doi-asserted-by":"crossref","first-page":"9059","DOI":"10.1021\/acs.jmedchem.8b01405","article-title":"Activity-based protein profiling delivers selective drug candidate ABX-1431, a monoacylglycerol lipase inhibitor, to control lipid metabolism in neurological disorders","volume":"61","author":"Jiang","year":"2018","journal-title":"J Med Chem"},{"key":"10.1007\/s13311-020-00914-6_bib58","unstructured":"Study of ABX-1431 in adult patients with Tourette syndrome or chronic motor tic disorder. ClinicalTrialsGov 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03625453 (accessed September 15, 2019)."},{"key":"10.1007\/s13311-020-00914-6_bib59","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1177\/0883073820913670","article-title":"Use of complementary and alternative medicine in children with Tourette syndrome","volume":"35","author":"Patel","year":"2020","journal-title":"J Child Neurol"},{"key":"10.1007\/s13311-020-00914-6_bib60","doi-asserted-by":"crossref","unstructured":"Hee Kim Y, Son C-G, Ku B-C, Won Lee H, Sook Lim H, Soo Lee M Herbal medicines for treating tic disorders: a systematic review of randomised controlled trials. 2014. https:\/\/doi.org\/10.1186\/1749-8546-9-6.","DOI":"10.1186\/1749-8546-9-6"},{"key":"10.1007\/s13311-020-00914-6_bib61","doi-asserted-by":"crossref","unstructured":"Zheng Y, Zhang ZJ, Han XM, Ding Y, Chen YY, Wang XF, et al. A proprietary herbal medicine (5-Ling granule) for Tourette syndrome: a randomized controlled trial. J Child Psychol Psychiatry Allied Discip 2016. https:\/\/doi.org\/10.1111\/jcpp.12432.","DOI":"10.1111\/jcpp.12432"},{"key":"10.1007\/s13311-020-00914-6_bib62","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s12264-017-0185-3","article-title":"Updated review on the clinical use of repetitive transcranial magnetic stimulation in psychiatric disorders","volume":"33","author":"Guo","year":"2017","journal-title":"Neurosci Bull"},{"key":"10.1007\/s13311-020-00914-6_bib63","doi-asserted-by":"crossref","unstructured":"Hsu C-W, Wang L-J, Lin P-Y. Efficacy of repetitive transcranial magnetic stimulation for Tourette syndrome: a systematic review and meta-analysis. Brain Stimul n.d.;11:1110\u20138. https:\/\/doi.org\/10.1016\/j.brs.2018.06.002.","DOI":"10.1016\/j.brs.2018.06.002"},{"key":"10.1007\/s13311-020-00914-6_bib64","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.nicl.2018.05.029","article-title":"Transcranial magnetic stimulation in obsessive-compulsive disorder: a focus on network mechanisms and state dependence","volume":"19","author":"Cocchi","year":"2018","journal-title":"NeuroImage Clin"},{"key":"10.1007\/s13311-020-00914-6_bib65","unstructured":"TICS: transcranial magnetic stimulation for intervening in children with Tourette's syndrome (CIHR). ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03844919?recrs=abdf&type=Intr&cond=Tourette+Syndrome&draw=2&rank=28 (accessed March 9, 2020)."},{"key":"10.1007\/s13311-020-00914-6_bib66","unstructured":"Multi-site transcranial magnetic stimulation therapy of the supplementary motor area in children with Tourette syndrome. ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03642951?recrs=abdf&type=Intr&cond=Tourette+Syndrome&draw=2&rank=8 (accessed March 9, 2020)."},{"key":"10.1007\/s13311-020-00914-6_bib67","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/archneur.57.8.1190","article-title":"Botulinum toxin in the treatment of tics","volume":"57","author":"Kwak","year":"2000","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-020-00914-6_bib68","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1212\/WNL.56.5.605","article-title":"Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial","volume":"56","author":"Marras","year":"2001","journal-title":"Neurology"},{"key":"10.1007\/s13311-020-00914-6_bib69","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s10072-003-0201-4","article-title":"Treatment of phonic tics in patients with Tourette's syndrome using botulinum toxin type A","volume":"24","author":"Porta","year":"2004","journal-title":"Neurol Sci"},{"key":"10.1007\/s13311-020-00914-6_bib70","doi-asserted-by":"crossref","unstructured":"Jankovic J. An update on new and unique uses of botulinum toxin in movement disorders. Toxicon 2018. https:\/\/doi.org\/10.1016\/j.toxicon.2017.09.003.","DOI":"10.1016\/j.toxicon.2017.09.003"},{"key":"10.1007\/s13311-020-00914-6_bib71","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.toxicon.2012.12.004","article-title":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders","volume":"67","author":"Hallett","year":"2013","journal-title":"Toxicon"},{"key":"10.1007\/s13311-020-00914-6_bib72","doi-asserted-by":"crossref","unstructured":"Caligiore D, Mannella F, Arbib MA, Baldassarre G. Dysfunctions of the basal ganglia-cerebellar-thalamo-cortical system produce motor tics in Tourette syndrome. PLoS Comput Biol 2017;13. https:\/\/doi.org\/10.1371\/journal.pcbi.1005395.","DOI":"10.1371\/journal.pcbi.1005395"},{"key":"10.1007\/s13311-020-00914-6_bib73","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2147\/NDT.S139368","article-title":"Deep brain stimulation in Tourette's syndrome: evidence to date","volume":"15","author":"Casagrande","year":"2019","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1007\/s13311-020-00914-6_bib74","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1002\/mds.23734","article-title":"Deep brain stimulation for Gilles de la Tourette syndrome: a case series targeting subregions of the globus pallidus internus","volume":"26","author":"Mart\u00ednez-Fern\u00e1ndez","year":"2011","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-020-00914-6_bib75","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jamaneurol.2017.4317","article-title":"Efficacy and safety of deep brain stimulation in Tourette syndrome: the international Tourette syndrome deep brain stimulation public database and registry","volume":"75","author":"Martinez-Ramirez","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-020-00914-6_bib76","doi-asserted-by":"crossref","unstructured":"Baldermann JC, Sch\u00fcller T, Huys D, Becker I, Timmermann L, Jessen F, et al. Deep brain stimulation for Tourette syndrome: a systematic review and meta-analysis. Brain Stimul n.d.;9:296\u2013304. https:\/\/doi.org\/10.1016\/j.brs.2015.11.005.","DOI":"10.1016\/j.brs.2015.11.005"},{"key":"10.1007\/s13311-020-00914-6_bib77","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1176\/appi.ajp.2012.11101583","article-title":"Deep brain stimulation of anteromedial globus pallidus interna for severe Tourette's syndrome","volume":"169","author":"Cannon","year":"2012","journal-title":"Am J Psychiatry"},{"key":"10.1007\/s13311-020-00914-6_bib78","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3171\/2018.7.PEDS18300","article-title":"Deep brain stimulation for Gilles de la Tourette syndrome in children and youth: a meta-analysis with individual participant data","volume":"23","author":"Coulombe","year":"2018","journal-title":"J Neurosurg Pediatr"},{"key":"10.1007\/s13311-020-00914-6_bib79","doi-asserted-by":"crossref","unstructured":"Johnson KA, Fletcher PT, Servello D, Bona A, Porta M, Ostrem JL, et al. Image-based analysis and long-term clinical outcomes of deep brain stimulation for Tourette syndrome: a multisite study. J Neurol Neurosurg Psychiatry 2019. https:\/\/doi.org\/10.1136\/jnnp-2019-320379.","DOI":"10.1136\/jnnp-2019-320379"},{"key":"10.1007\/s13311-020-00914-6_bib80","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S1474-4422(17)30160-6","article-title":"Anterior pallidal deep brain stimulation for Tourette's syndrome: a randomised, double-blind, controlled trial","volume":"16","author":"Welter","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-020-00914-6_bib81","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1474-4422(15)00008-3","article-title":"Bilateral globus pallidus stimulation for severe Tourette's syndrome: a double-blind, randomised crossover trial","volume":"14","author":"Kefalopoulou","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-020-00914-6_bib82","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/mds.27645","article-title":"Long-term effects of anterior pallidal deep brain stimulation for Tourette's syndrome","volume":"34","author":"Welter","year":"2019","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-020-00914-6_bib83","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/jamapsychiatry.2014.2650","article-title":"Lifetime prevalence, age of risk, and genetic relationships of comorbid psychiatric disorders in Tourette syndrome","volume":"72","author":"Hirschtritt","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1007\/s13311-020-00914-6_bib84","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00787-012-0278-5","article-title":"Tourette syndrome in youth with and without obsessive compulsive disorder and attention deficit hyperactivity disorder","volume":"21","author":"Lebowitz","year":"2012","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1007\/s13311-020-00914-6_bib85","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.biopsych.2006.09.035","article-title":"Tics moderate treatment outcome with sertraline but not cognitive-behavior therapy in pediatric obsessive-compulsive disorder","volume":"61","author":"March","year":"2007","journal-title":"Biol Psychiatry"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-020-00914-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-020-00914-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923012667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923012667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-020-00914-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:55:24Z","timestamp":1761807324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923012667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":85,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1878747923012667"],"URL":"https:\/\/doi.org\/10.1007\/s13311-020-00914-6","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-020-00914-6","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}